{"result": {"id": "chatcmpl-164", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "Anti-angiogenic therapies are a type of therapy used in cancer treatment. These treatments aim to block the formation of new blood vessels, which is essential for tumor growth and survival.  They are also considered a class of treatments for cancer, specifically targeting the process of angiogenesis. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743185905, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 58, "prompt_tokens": 206, "total_tokens": 264, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"ANTI-ANGIOGENIC THERAPIES\"\nDescription List: [\"Anti-angiogenic therapies are a type of therapy used in cancer treatment. These treatments aim to block the formation of new blood vessels, which is essential for tumor growth and survival.  They are also considered a class of treatments for cancer. \\n\", \"Treatments targeting the process of angiogenesis\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_fe8aeda0ff476bc95fe3abd959177336731a2ea72d761a7c8992c0dd939f5f89_v2"}